Le Lézard
Classified in: Health
Subjects: SCZ, FVT, DEI

Enhabit Home Health & Hospice announces participation in upcoming investor meetings


DALLAS, Aug. 23, 2022 /PRNewswire/ -- Enhabit Home Health & Hospice (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in the following events:

Enhabit's President and Chief Executive Officer Barbara Jacobsmeyer and Chief Financial Officer Crissy Carlisle will participate in a fireside chat on Thursday, Sept. 8, 2022 at 4:20 p.m. ET. The presentation will be webcast live and available at https://investors.ehab.com.  

About Enhabit Home Health & Hospice  
Enhabit Home Health & Hospice is a leading national home health and hospice provider working to expand what's possible for patient care in the home. The company's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 251 home health locations and 100 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.  

Investor relations contact
Jennifer Hills
[email protected] 
469-621-6496

Media contact
Erin Volbeda
[email protected] 
972-338-5141

SOURCE Enhabit Home Health & Hospice


These press releases may also interest you

at 21:07
ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals
Fellow Aurinia Shareholders, ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") and has been supportive of the Company's mission since 2010...

at 20:51
Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major...

at 20:30
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Alvotech , today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult...

at 20:05
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under...

at 19:42
NOTICE OF ANNUAL GENERAL MEETING IN IMMUNOVIA AB (PUBL)
The shareholders in Immunovia AB (publ), Reg. No. 556730-4299, are hereby invited to the Annual General Meeting ("AGM") to be held at The Spark, Scheeletorget 1, Medicon Village, in Lund on Wednesday 19 June 2024 at 10 a.m. CEST. Right to...

at 18:54
Immunovia carries out a rights issue of units of approximately SEK 70 million and raises bridge loans
The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today,...

More news about Health...


News published on and distributed by: